MedPath

Alpha MSH in Ocular Disease

Not Applicable
Completed
Conditions
Advanced Dry Macular Degeneration
Interventions
Device: Alpha MSH assay
Registration Number
NCT03451578
Lead Sponsor
Duke University
Brief Summary

The purpose of this study is gain a better understanding of a molecule called alpha melanocyte stimulating hormone (alpha MSH) and its potential role in your retinal disease. Alpha MSH has been shown to have an important role in the regulation of ocular immunity in animal models of inflammatory retinal diseases and retinal dystrophies, and there may be a protective effect of alpha MSH. By studying the levels of alpha MSH in your eye we may better understand its role in advanced dry macular degeneration. By studying the levels of this molecule we hope to better understand if it may be a good target for future treatment.

Detailed Description

A small amount (0.1 mL) of aqueous humor would be removed from the study eye in the clinic setting. This sample will be processed and then sent off for measurement of alpha MSH levels.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
54
Inclusion Criteria
  • 60 years or older
  • diagnosis of advanced dry macular degeneration with foveal geographic atrophy
  • limited vision or blindness (20/100 or worse) in that eye
  • pseudophakia (prior cataract surgery in that eye)
Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Advanced Dry macular degenerationAlpha MSH assay-
Primary Outcome Measures
NameTimeMethod
Level of Alpha Melanocyte Stimulating Hormone as Measured by Enzyme-linked Immunosorbent Assay2 hours
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Duke University Eye Center

🇺🇸

Durham, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath